Mrturdinu now what? GLTO shorts
$1.3T of equity wiped out in the oil market is going to put a wet blanket on the pharma market. Commodities cram down of 2008 headed this direction. This will not see $120 by the end of this week, next week or in a month. Absurd if you think $145 or $225. This is a great short.
Sentiment: Strong Sell
see slide 13: We are confident even with the expected level of future commercial competition that this long-term opportunity may result in a net product revenue reaching $1.5 billion for the U.S. Jakafi franchise in MPNs alone. Still lots of mumbo jumbo...
Can't wait for Maddies incyteful response.
trap door opening
CFO Frank (EX LUCENT / ALCATEL meger of Equals) “One of the nice things about Pfizer is we have the capacity to do any size deal that we want.”
buy out around the corner?
90's next week? Maybe, maybe not. Stay tuned.
experienced strong growth in the second quarter. It is the first JAK inhibitor indicated for the treatment
of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known
as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential
thrombocythemia myelofibrosis. Jakavi is currently approved in more than 80 countries, including EU
member states, Japan and Canada. In March 2015, the EC approved Jakavi for the treatment of adult
patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. Jakavi is the
first targeted treatment approved by the EC for these patients. Regulatory applications have also been
submitted in Switzerland, Japan and other countries for Jakavi in the PV indication. Novartis licensed
ruxolitinib from Incyte Corporation for development and commercialization outside the US. Ruxolitinib
is marketed in the US by Incyte under the brand name Jakafi®.
A preplanned analysis at 18 months of the pivotal Phase III RESPONSE study showed that 80% of patients with polycythemia vera (PV) treated with Jakavi (ruxolitinib) who responded at Week 32 experienced a durable response for at least one year.
Underpinning our financial results in the second quarter is a continued focus on key growth drivers, including Gilenya, Afinitor, Tasigna, Xolair, Tafinlar/Mekinist and Jakavi, as well as Emerging Growth Markets.
Isn't INCY bigger than this? Joe Jimenez, CEO of Novartis, says the company is looking for bolt-on acquisitions worth between $1 bilion to $3 billion, rather than mega-mergers.
Reports Q2 (Jun) earnings of $1.27 per share, $0.05 worse than the Capital IQ Consensus Estimate of $1.32; revenues fell 13.3% year/year to $12.69 bln vs the $12.59 bln consensus.
Pharmaceuticals net sales reached $7.8 billion (-4%, +6% cc), with volume growth of 13 percentage points, which includes the new oncology assets acquired from GSK (sales of $0.5 billion in Q2), and a positive price impact of 1 percentage point, partly offset by the negative impact of generic competition (- 8 percentage points), largely for Diovan monotherapy, Exforge and Vivelle-Dot in the US.
Growth Products - which include Gilenya, Lucentis, Afinitor, Tasigna, Xolair, the COPD portfolio, the Tafinlar/Mekinist combination and Jakavi - generated $3.5 billion or 44% of division net sales.
These products grew 38% (cc) over the same period last year.